Skip to main content

Table 2 Mean values and SD’s for mindfulness (MT-Group) and pharmacology (MED-Group) at each measurement period

From: Mindfulness and pharmacological prophylaxis after withdrawal from medication overuse in patients with Chronic Migraine: an effectiveness trial with a one-year follow-up

 

MT-Group

Med-Group

 

Baseline

3-MO

6-MO

12-MO

Baseline

3-MO

6-MO

12-MO

Headaches Frequency

18.5 ± 7.2

8.3 ± 3.5

10.4 ± 6.9

12.4 ± 8.5

18.5 ± 7.2

8.9 ± 8.0

11.4 ± 8.0

10.4 ± 7.2

Medications intake

17.7 ± 5.9

8.1 ± 4.6

8.9 ± 4.2

10.3 ± 5.4

15.4 ± 4.4

8.8 ± 8.4

11.0 ± 7.6

8.6 ± 4.8

HIT-6

65.3 ± 5.7

62.0 ± 5.7

60.7 ± 10.8

64.5 ± 7.0

66.9 ± 5.2

60.7 ± 7.7

62.6 ± 6.3

61.5 ± 4.8

MIDAS

65.4 ± 43.5

39.0 ± 36.7

41.5 ± 51.7

53.7 ± 52.6

82.9 ± 40.0

26.7 ± 23.5

38.8 ± 25.4

51.5 ± 50.2

BDI-13

13.4 ± 5.9

9.0 ± 6.3

9.0 ± 5.3

10.3 ± 6.8

13.3 ± 6.8

6.2 ± 6.3

8.0 ± 5.9

7.6 ± 6.4

STAI-T

52.3 ± 9.8

48.6 ± 8.4

48.6 ± 7.7

50.9 ± 9.5

52.8 ± 10.2

48.5 ± 9.4

51.3 ± 9.9

48.4 ± 9.6

STAI-S

47.0 ± 6.8

45.4 ± 6.4

45.5 ± 6.9

49.9 ± 9.3

49.6 ± 7.8

47.2 ± 6.1

48.3 ± 10.7

48.6 ± 8.7

  1. N = 19 for MT-Group and N = 20 for MED-Group
  2. Note. Values are expressed as means ± SD